Table 3.
Distribution of Pediatric AML Mortality and Hazard Risk Associated with Various Prognostic Factors, SEER 1973–2012
| Variable | Number of Death n (%) | HR (95% CI) | p-value |
|---|---|---|---|
| Age at Diagnosis | |||
| < 1 year | 150 (46) | 1.00 | - |
| 1 – 4 years | 365 (43) | 0.85 (0.7, 1.02) | 0.08 |
| 5 – 9 years | 246 (45) | 0.77 (0.63, 0.95) | 0.01 |
| 10 – 14 years | 429 (51) | 0.98 (0.81, 1.18) | 0.79 |
| 15 – 19 years | 572 (53) | 1.1 (0.92, 1.32) | 0.31 |
| Sex | |||
| Female | 831 (48) | 1.00 | - |
| Male | 931 (49) | 1.05 (0.96, 1.16) | 0.27 |
| Race/Ethnicity | |||
| Caucasian | 911 (49) | 1.00 | |
| African American | 243 (56) | 1.29 (1.12, 1.49) | <0.001 |
| Hispanic | 508 (56) | 1.17 (1.04, 1.32) | 0.01 |
| Other | 224 (53) | 1.05 (0.9, 1.22) | 0.54 |
| US Region | |||
| Eastern | 428 (43) | 1.00 | - |
| Pacific Coast, Alaska | 843 (46) | 1.08 (0.96, 1.22) | 0.20 |
| Northern Plains | 310 (61) | 1.06 (0.91, 1.24) | 0.44 |
| South West | 181 (57) | 1.23 (1.03, 1.46) | 0.02 |
| AML Subtypes | |||
| 9866/3: APL | 125 (30) | 1.00 | - |
| 9861/3: AML | 1071 (56) | 1.7 (1.41, 2.06) | <0.001 |
| 9840/3: AEL | 36 (61) | 2.2 (1.52, 3.2) | <0.001 |
| 9865/3: AML with t(6;9) | - | 0 (0, 0) | 0.91 |
| 9867/3: AMML | 157 (50) | 1.93 (1.52, 2.44) | <0.001 |
| 9871/3: AML with inv(16) | 9 (16) | 0.64 (0.32, 1.25) | 0.19 |
| 9872/3: AML w/ min diff | 63 (58) | 2.39 (1.76, 3.25) | <0.001 |
| 9873/3: AML w/o mat | 55 (44) | 1.79 (1.3, 2.46) | <0.001 |
| 9874/3: AML w/ mat | 76 (39) | 1.41 (1.06, 1.88) | 0.02 |
| 9895/3: AML w/ MDS | 11 (33) | 1.46 (0.79, 2.71) | 0.23 |
| 9896/3: AML t(8;21) | 17 (25) | 1 (0.6, 1.66) | 0.99 |
| 9897/3: AML with t(9;11) | 13 (31) | 1.52 (0.86, 2.69) | 0.15 |
| 9898/3: AML w/ DS | 1 (4) | 0.3 (0.04, 2.17) | 0.23 |
| 9910/3: AMKL | 99 (42) | 1.57 (1.2, 2.04) | 0.001 |
| 9911/3: AML with t(1;22) | 1 (50) | 7.5 (1.04, 54.15) | 0.05 |
| 9920/3: t-AML | 28 (55) | 4.26 (2.8, 6.48) | <0.001 |
Note: AML: Acute Myeloid Leukemia; HR: Hazards Ratio; CI: Confidence Interval; ;9866/3: Acute Promyelocytic Leukemia (APL); 9861/3: Acute Myeloid Leukemia (AML); 9840/3: Acute Erythroid Leukemia (AEL); 9865/3: AML with t(6;9); 9867/3: Acute Myelomonocytic Leukemia (AMML); 9871/3: AML with inv(16); 9872/3: AML with minimal differentiation; 9873/3: AML without maturation; 9874/3: AML with maturation; 9895/3: AML with myelodysplasia-related changes (AML w/MDS); 9896/3: AML t(8;21); 9897/3: AML with t(9;11); 9898/3: Myeloid Leukemia with Down Syndrome (AML w/ DS); 9910/3: Acute Megakaryoblastic Leukemia (AMKL); 9911/3: AML with t(1;22); 9920/3: Therapy-related Acute Myeloid Neoplasm (t-AML)